Inclusion Criteria:
* Aged 18-75 years;
* ECOG performance status 0-1;
* Postoperative histopathology confirms R0 resection with TNM stage I pulmonary adenocarcinoma;
* Confirmed ALK fusion-positive by FISH, IHC, or NGS;
* No prior systemic treatment after surgery;
* At least one high-risk recurrence factor: poorly differentiated tumor, vascular invasion, wedge resection, visceral pleura involvement, uncertain lymph node status, intrapulmonary dissemination;
* Able to start Ensartinib adjuvant therapy within 4-8 weeks after surgery;
* Hematological, biochemical, and organ function requirements met: Hemoglobin ≥100 g/L; Absolute neutrophil count ≥1.5×10\^9/L; Platelet count ≥100×10\^9/L; Total bilirubin ≤2 times the upper limit of normal; ALT and AST ≤2.5 times the upper limit of normal; Creatinine ≤1.5 times the upper limit of normal; Creatinine clearance ≥60 mL/min;
* Women of childbearing potential must have a negative urine pregnancy test - within 7 days prior to starting treatment;
* Informed consent obtained from the patient or their legal representative;
* Men and women of childbearing potential must agree to use reliable - contraception from enrollment in the study until 8 weeks after discontinuation of the study drug.
Exclusion Criteria:
* Previous systemic treatment for NSCLC;
* Previous local radiotherapy for NSCLC;
* Unable to take oral medications;
* Known allergy to Ensartinib or any component of this product;
* History of interstitial lung disease, drug-induced interstitial disease, radiation pneumonitis requiring steroid treatment, or any clinically evident active interstitial lung disease; baseline CT scan showing idiopathic pulmonary fibrosis;
* Any unstable systemic diseases, including: active infections, uncontrolled hypertension, unstable angina, angina onset within the last 3 months, congestive heart failure (≥ NYHA class II), myocardial infarction (within 6 months prior to enrollment), severe arrhythmias requiring medication, liver, kidney, or metabolic diseases;
* Pregnant or breastfeeding women;
* History of definite neurological or psychiatric disorders, including epilepsy or dementia;
* Any other conditions that the investigator deems unsuitable for enrollment.
